Researcher
Niels Vande Casteele
- Disciplines:Laboratory medicine, Regenerative medicine, Other basic sciences, Other health sciences, Other medical and health sciences, Medical biotechnology, Pharmaceutics, Drug discovery and development
Affiliations
- Therapeutic and Diagnostic Antibodies (Division)
Member
From1 Apr 2013 → 30 Sep 2016
Projects
1 - 1 of 1
- Translating therapeutic drug monitoring of biopharmaceuticals into individualised care of inflammatory bowel disease patients through pharmacometric modelling en farmaco-economic evaluation.From1 Oct 2013 → 30 Sep 2016Funding: FWO fellowships
Publications
1 - 10 of 58
- Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-based vs Trough Concentration-based Dosing of Infliximab(2018)
Authors: Marc Ferrante, Gert Van Assche, Paul Rutgeerts, João Guedelha Sabino, Niels Vande Casteele, Ann Gils, Séverine Vermeire
Pages: 1276 - 1283.e1 - Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial(2018)
Authors: Thomas Van Stappen, Niels Vande Casteele, Gert Van Assche, Marc Ferrante, Séverine Vermeire, Ann Gils
Pages: 818 - 826 - Evolving Concepts in Phases I and II Drug Development for Crohn's Disease(2017)
Authors: Niels Vande Casteele
Pages: 246 - 255 - Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation(2016)
Authors: Thomas Van Stappen, Lize Bollen, Niels Vande Casteele, Gert Van Assche, Marc Ferrante, Séverine Vermeire, Ann Gils
- Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation(2016)
Authors: Niels Vande Casteele
Pages: 1685 - 1696 - Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab(2016)
Authors: Thomas Billiet, Niels Vande Casteele, Ann Gils, Marc Ferrante, Gert Van Assche, Paul Rutgeerts, Séverine Vermeire
Pages: 1015 - 1023 - Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results(2016)
Authors: Niels Vande Casteele
Pages: 1302 - 1309 - Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial(2016)
Authors: Niels Vande Casteele, Marc Ferrante, Ann Gils, Séverine Vermeire
Pages: 1126 - 1131 - Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis(2016)
Authors: Thomas Van Stappen, Niels Vande Casteele, Ann Gils, Thomas Billiet, Gert Van Assche, Paul Rutgeerts, Séverine Vermeire, Marc Ferrante
Pages: 543 - 549 - Analytical and clinical validation of a rapid point-of-care assay for infliximab quantification in patients with ulcerative colitis(2016)
Authors: Thomas Van Stappen, Lize Bollen, Niels Vande Casteele, Konstantinos Papamichael, Nick Geukens, Chris Barthel, Yessica Kölmel, Nasim Zali, Steffen Rameil, Gert Van Assche, et al.
Pages: S145 - S145